Development of Non-Hallucinogenic Neuroplastogens Targeting 5-HT2A for the Treatment of Psychiatric Disorders
Time: 8:50 am
day: Day Two
Details:
- Highlighting the profound therapeutic efficacy of psychedelics across numerous preclinical studies and clinical trials in psychiatry and neurology, and the commercialization involved in scaling access to psychedelic medicines.
- Describing the rational design and optimization of both hallucinogenic and nonhallucinogenic 5-HT2A agonists for clinical development.
- Discussing Xylo’s pipeline of novel neuroplastogens and the identification of development candidate PSYLO-1001